New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Vyome Holdings, Inc.

HIND

Healthcare Biotechnology

Vyome Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $319,700.00, up 24.4% from fiscal 2024.

Revenue
+67.6%
EPS
n/m
Free cash flow
n/m

Quarter to September 2026, against a year earlier

1.20 0.25 −17.24%
Market cap
$10.2M
P/E
n/m
Fwd P/E FY26e
n/m
Dividend yield
—
F-score
4/9
ROIC
0.00%
Net debt / EBITDA
0.5×
Payout ratio
—

Ratios over time FY16 to FY25

Returns on capital

ROIC was 0.00% in FY25, the highest of these ten years. ROE, at 3,263.0%, is far above it because equity is small against the capital the business uses.

ROEROIC
FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
ROE−446.6%−69.9%−155.0%−163.5%−142.6%−214.7%−192.6%−220.6%−127.4%3263.0%
ROIC0.0%−3384.9%0.0%−496.9%−32.1%−166.0%0.0%−457.0%0.0%0.0%

Debt

Net debt is 0.48× a year’s EBITDA.

Net debt / EBITDA
FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Net debt / EBITDA3.4×1.0×0.4×0.6×−1.1×0.4×0.1×0.3×−3.5×0.5×

Cash cycle, in days

Customers pay in 1402 days, inventory is held 14482 days and suppliers are paid in 5685. Cash is tied up for 10200 days between paying for goods and being paid.

Cash cycleDays to pay suppliersDays to be paid
FY16FY17FY18FY19FY20FY21FY22FY23FY24
Cash cycle8616663191−184320930910200
Days to pay suppliers779678802652411581975685
Days to be paid551553532857671701402

Per share, from FY15

Since FY15, per share: revenue has fallen 32.0% a year.

Revenue
FY15FY16FY17FY18FY19FY20FY22FY23FY24FY25
Revenue1.0×0.1×0.1×0.7×0.1×0.4×15945.8×1231.1×151.2×0.0×
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
Piotroski F-Score
4 5 5 — — 5 2 4 4 4
P/E ratio
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
P/S ratio
63.32 0.02 0.18 0.81 0.00 451,056.17 2,371,432.79 3,767,622.90 104,890,153.82 99,162,871.79
Altman Z-Score
(22.00) (63.09) (86.44) (90.57) — 135,446.38 1,027,362.74 1,190,653.79 32,066,190.82 13,476,384.94
P/FCF ratio
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z″-Score (non-manufacturers)
(50.57) (162.29) (198.25) (208.64) (34.80) (47.34) (26.97) (20.87) (3.98) 5.95
P/Operating CF
(13.32) (30.76) (0.63) (3.21) 0.00 (2,892,442.50) (1,594,726.58) (6,332,250.42) (113,067,411.66) (58,261,406.75)
Beneish M-Score
— 17.90 (0.23) (14.50) (6.74) 4.01 (1.68) (4.60) (0.02) (2.18)
P/B ratio
5.38 0.00 0.23 2.48 0.00 351,797.04 490,925.04 2,616,093.39 29,615,270.27 5,232,246.70
EV/Sales
48.50 0.88 (0.35) 0.47 (1.66) 451,057.04 2,371,428.85 3,767,621.38 104,890,150.35 99,162,852.46
EV/EBITDA
0.00 0.00 0.20 0.00 0.41 0.00 0.00 0.00 0.00 0.00
EV/FCF
(4.14) (5.83) 0.18 (0.24) 1.43 (570,077.57) (337,409.28) (1,116,400.41) (32,838,000.14) (17,061,843.73)
Current Ratio
1.99 0.05 2.73 1.32 3.98 0.77 4.59 1.66 5.17 17.00
Net Debt/EBITDA
0.48 (3.53) 0.30 0.09 0.41 (1.07) 0.58 0.38 1.01 3.43
Debt/Equity
0.00 (0.82) 0.00 0.05 0.01 0.88 0.07 0.76 0.28 0.15
ROE
3,262.96% (127.42%) (220.59%) (192.58%) (214.71%) (142.60%) (163.53%) (155.04%) (69.94%) (446.59%)
ROA
(260.50%) (24.04%) (104.44%) (145.16%) (140.96%) (75.30%) (93.25%) (89.55%) (52.72%) (44.02%)
ROIC
0.00% 0.00% (456.96%) 0.00% (165.96%) (32.10%) (496.88%) 0.00% (3,384.94%) 0.00%
Return on Tangible Assets
(373.23%) 26.91% (173.08%) (1,477.43%) (264.63%) 1,041.41% (154.35%) (284.15%) (80.68%) (27.59%)
Average Days of Receivables
— 1,402.32 69.78 70.79 75.55 84.64 31.71 34.89 155.48 55.40
Earnings Yield
(44,674.97%) (544.96%) (719.36%) (695.33%) (152.18%) (11.36%) (33.77%) (18.89%) 0.00% (5.58%)
Free Cash Flow Yield
(18.51%) (688.12%) (1,096.56%) (242.13%) 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow per Share
(1.73) (2,546.89) (16,970.00) (219,940.00) — (2.29) (4.90) (16.13) (1.89) (4.67)
Book value per Share
1.74 (18,219.92) 6,663.00 36,610.00 — 3.71 3.37 6.88 2.10 15.23
Free Cash Flow
(3.75) (0.61) (16.97) (21.99) (15.73) (8.94) (23.06) (30.71) (31.67) (19.72)
EV/EBIT
0.00 0.00 0.20 0.00 0.39 0.00 0.00 0.00 0.00 0.00
Other line items

Show all line items

Columns are period end dates · fundamentals updated Nov 18, 2026